logo
Plastic Surgery Career Path: Tips for Med Students

Plastic Surgery Career Path: Tips for Med Students

Medscape26-05-2025
Plastic surgery covers a wide range of subspecialties, all of which focus on restoring physical function or appearance. In addition to reconstructive and cosmetic (or aesthetic) — which represent the two main types of plastic surgery — subspecialties include microsurgery (the reconnection of small blood vessels and nerves in transplant cases and other circumstances) and gender-affirming surgery, among others.
The American Board of Plastic Surgery, Inc., reported that as of January 2025, there were approximately 7752 actively practicing plastic surgeons in the United States. The need for more surgeons to fill certain geographic gaps in patient access and meet the rising demand for a range of procedures suggests that a plastic surgery specialty may offer plenty of opportunity for individuals interested in helping people restore their self-confidence and independence.
To offer more insight to medical students thinking of pursing a plastic surgery specialty, we turned to Scott Hollenbeck, MD, chair of the Department of Plastic and Maxillofacial Surgery, University of Virginia Health, Charlottesville, Virginia, and president of the American Society of Plastic Surgeons.
Q: When did you decide to specialize in plastic surgery, and what helped you choose that direction?
A: I decided pretty late in my training. I was a third-year general surgery resident, and I was exposed to plastic surgery during our breast oncology rotation.
There was a plastic surgeon who asked me if I wanted to help them as they did the reconstruction following a mastectomy. I did that on several occasions and found it to be very enjoyable to 'rebuild' a patient rather than deconstruct their body through surgery.
One day, he said to me: 'You should be a plastic surgeon. You have the right skills and demeanor and will have a great career.' I saw how grateful his patients were and was convinced it would be a great career for me, and it really has.
Q: What is a typical week's schedule for a plastic surgeon, and how is your time divided between surgery, office consultations, and other matters?
A: I do a lot of different things beyond surgery and clinical care, but at least that aspect of my job is about 40 hours — or 3 days a week.
I usually dedicate one day to my obligations as a department chair and the administrative work associated with that, and one day to running my research efforts.
Now, in reality, it's not that defined. These different activities usually blend into each other throughout the week and sometimes into the weekend.
Q: How do you balance a patient's expectations with realistic possibilities?
A: That is an important point. It's all about informed consent. I never try to 'sell' a patient a surgery.
Instead, I try to explain the nature of the procedure and the potential complications and describe a realistic outcome.
Sometimes, I will share pictures with them and maybe even connect them with a prior patient who has expressed interest in serving as a resource for future patients.
Many patients use social media to get information from other patients from around the country, and this, too, can be helpful in establishing realistic expectations.
Q: How has the field of plastic surgery changed in recent years, and what is on the horizon?
A: Plastic surgery is always changing. We are known as the specialty for innovation. As such, we often create a new surgical field, which, in many cases, is then adopted by another surgical field.
Did you know the first kidney transplant was performed by a plastic surgeon? In fact, Dr Joseph Murray received the Nobel Prize for this achievement.
The past few years have seen a lot of work in the use of biomaterials to rebuild the body after trauma or cancer, as well as the use of computers to plan surgeries and robotic machinery to assist the plastic surgeon in performing very delicate procedures.
Q: What should students understand about the challenges and rewards of a plastic surgery specialty?
A: It is a challenging career, both physically and emotionally, but it is exceptionally rewarding to help patients get through difficult situations.
This applies to both reconstructive and aesthetic procedures. The skills we use are related to the transfer and reshaping of tissues to achieve a result that helps the patient in both their form and function.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA Calls for Better Opioid Safety Labeling
FDA Calls for Better Opioid Safety Labeling

Medscape

time6 minutes ago

  • Medscape

FDA Calls for Better Opioid Safety Labeling

The FDA is requiring manufacturers of opioid pain medications to update safety labels to better emphasize risks linked to their long-term use, the agency announced in a new Drug Safety Communication. The changes are based on observations from a May meeting between the Drug Safety and Risk Management Advisory Committee and the Anesthetic and Analgesic Drug Products Advisory Committee, which met to discuss two postmarketing requirement studies that assessed risk for abuse, addiction, and overdose in long-term use of opioid analgesics. One of the observational studies showed that over 12 months of use, 1%-6% of the more than 2000 total participants met criteria for opioid addiction, 9% met criteria for prescription opioid abuse, and 22% met criteria for prescription opioid misuse. In the second study, 5-year cumulative incidence estimates for opioid overdose-related death ranged from 1.5%-4.0%. In addition, 17% of first opioid overdoses over the entire 5-11 year study period were fatal. The new safety-labeling requirements are a result of these findings, committee and public comments from the meeting, and recognition that there is currently an 'absence of adequate and well-controlled studies on long-term opioid effectiveness,' the FDA noted in a press release. 'The death of almost 1 million Americans during the opioid epidemic has been one of the cardinal failures of the public health establishment,' FDA commissioner Marty Makary, MD, said in the release. 30-Day Warning The FDA has also called for a new prospective, randomized controlled trial to be conducted that will focus primarily on assessing risks and benefits of opioids used over the long term. For now, the updated labeling should include a better explanation of risks, stronger warnings about higher doses, clarification about use limits, an emphasis that long-acting or extended-release opioids should only be used if shorter-acting opioids or other medications have proven inadequate, and a reminder about serious harm that can come if a patient who becomes physically dependent does not stop opioid use. Additionally, the revised labels should provide information on possible opioid-related problems with the esophagus; on opioid overdose reversal agents; on toxic leukoencephalopathy, which can occur after overdose; and on negative drug-drug interactions, including gabapentinoids. 'This long-overdue labeling change is only part of what needs to be done — we also need to modernize our approval processes and postmarket monitoring,' Makary said. The release noted that OxyContin's drug application was first approved without supportive long-term use data. The FDA added that manufacturers have 30 days to submit the newly required labeling updates for review.

All major Las Vegas Strip casinos are now unionized in historic labor victory
All major Las Vegas Strip casinos are now unionized in historic labor victory

Washington Post

time7 minutes ago

  • Washington Post

All major Las Vegas Strip casinos are now unionized in historic labor victory

LAS VEGAS — When Susana Pacheco accepted a housekeeping job at a casino on the Las Vegas Strip 16 years ago, she believed it was a step toward stability for her and her 2-year-old daughter. But the single mom found herself exhausted, falling behind on bills and without access to stable health insurance, caught in a cycle of low pay and little support. For years, she said, there was no safety net in sight — until now.

QuidelOrtho (QDEL) Q2 Earnings Report Preview: What To Look For
QuidelOrtho (QDEL) Q2 Earnings Report Preview: What To Look For

Yahoo

time16 minutes ago

  • Yahoo

QuidelOrtho (QDEL) Q2 Earnings Report Preview: What To Look For

Healthcare diagnostics company QuidelOrtho (NASDAQ:QDEL) will be reporting results this Tuesday afternoon. Here's what you need to know. QuidelOrtho met analysts' revenue expectations last quarter, reporting revenues of $692.8 million, down 2.6% year on year. It was a mixed quarter for the company, with a solid beat of analysts' EPS estimates but a slight miss of analysts' full-year EPS guidance estimates. Is QuidelOrtho a buy or sell going into earnings? Read our full analysis here, it's free. This quarter, analysts are expecting QuidelOrtho's revenue to decline 4.1% year on year to $611 million, in line with the 4.2% decrease it recorded in the same quarter last year. Adjusted earnings are expected to come in at $0.01 per share. Analysts covering the company have generally reconfirmed their estimates over the last 30 days, suggesting they anticipate the business to stay the course heading into earnings. QuidelOrtho has only missed Wall Street's revenue estimates once over the last two years, exceeding top-line expectations by 4.2% on average. Looking at QuidelOrtho's peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. GE HealthCare delivered year-on-year revenue growth of 3.5%, beating analysts' expectations by 1%, and Hologic reported revenues up 1.2%, topping estimates by 1.7%. GE HealthCare traded down 8.3% following the results while Hologic was up 2.9%. Read our full analysis of GE HealthCare's results here and Hologic's results here. Questions about potential tariffs and corporate tax changes have caused much volatility in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. QuidelOrtho is down 21.9% during the same time and is heading into earnings with an average analyst price target of $47.14 (compared to the current share price of $22.81). When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we've found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback. StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store